Bioflavonoid hesperidin possesses the anti-hyperglycemic and hypolipidemic property in STZ induced diabetic myocardial infarction (DMI) in male Wister rats

The aim of our study was to evaluate the hesperidin anti-hyperglycemic and hypo-lipidemic effects on diabetic myocardial infraction (DMI) rats by decreasing the blood glucose and blood cholesterol contents. The object of the study was to examine the 7groups of male Wistar rats, each group contains 6 rats, Group I (normal), Group II diabetic (control) and 5(experimental) groups, i.e., Group III (diabetic + hesperidin), Group IV (diabetic + Glibenclamide), Group V (ISO), Group VI (diabetic + ISO) and Group VII (diabetic + ISO + hesperidin). By that intake of hesperidin regulates the lipid and carbohydrate metabolism by decreasing the cholesterols in blood and plasma insulin by hyperlipidamic and anti-hyperglycemic activity. The rats turns to diabetic with single intraperitonial STZ injection (50 mg/kg BW), and from the second week the rats diet were switched to a high fat diet, i.e., cholesterol (40%), fat (50%), Protein (50%) turns to be hyperlipidamic rats and with Isoproterenol (ISO) single intraperitoneal injection by the (11 mg/kg BW) turns to DMI rats. The DMI rats fed with the hesperidin 100mg/kg BW for 4 weeks had significantly reduced the blood glucose (P < 0.05), total cholesterol (TC), Triglycerides, HDL, LDL and VLDL concentrations, when compared with experimental groups (p < 0.05). A significantly increased blood glucose and body weight was observed in hesperidin treated diabetic groups (P < 0.05) by comparing with the experimental groups. In conclusion, orally supplementation of hesperidin possesses a significant decrease in total blood lipid profiles and plasma insulin concentrations accompanied by the anti-hyperglycemic, hypo-lipidemic activity in DMI rats.